MAPT and Alzheimer disease: As the disease is believed to start more than 20years before any clinical symptoms appear, there is a need for detailedphenomic characterization.1,2 The classical hallmarksof AD are amyloid-β (Aβ) plaque deposition, and formationof neurofibrillary tangles made up of hyperphosphorylated tau proteins.Consequently, disease-modulating strategies have historically focusedon targeting the peptides involved in these pathologies, Aβand tau.